

Canine Nikkomycin Z Study – End Visit

<b>Study No.</b>	Identification number used for study subjects
<b>EndDate</b>	Date of final visit for study participants, expressed in mm/dd/yyyy
<b>AdverseEffects</b>	Any potential adverse effects noted by the owner on a survey completed at this visit
<b>Response</b>	The owner's assessment of the dog's response to treatment at this point in the study
<b>Weight</b>	The dog's weight at the final study visit, expressed in kilograms
<b>ScorePart1</b>	One point for each new or persistent clinical sign reported by the owner or veterinarian
<b>ScorePart2</b>	One point each for changes in CBC and serum chemistries (hyperproteinemia/hyperglobulinemia, monocytosis, and/or neutrophilia/leukocytosis)
<b>ScorePart3</b>	Immunodiffusion score <ul style="list-style-type: none"> <li>• <math>\leq 1:2 = 0</math> points</li> <li>• 1:4, 1:8 = 1 point</li> <li>• 1:16, 1:32 = 2 points</li> <li>• <math>\geq 1:64 = 3</math> points</li> </ul>
<b>ScorePart4</b>	Two points for new or unchanged thoracic radiographic lesions, one point for 50% or greater resolution of radiographic lesions compared to enrollment, and zero points for full resolution of radiographic lesions
<b>ScorePart5</b>	Two points each for positive culture or cytology/histopathology
<b>Dz.Score (End)</b>	The disease score assessed at the end study visit, determined by the summation of ScoreParts 1 to 5.